FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2617763968> ?p ?o ?g. }

• W2617763968 endingPage "436" @default.
• W2617763968 startingPage "423" @default.
• W2617763968 abstract "Abstract Proinflammatory signals promote prostate tumorigenesis and progression, but their origins and downstream effects remain unclear. We recently demonstrated that the expression of an innate immune receptor, TLR9, by prostate cancer cells is critical for their tumor-propagating potential. We investigated whether cancer cell–intrinsic TLR9 signaling alters composition of the prostate tumor microenvironment. We generated Ras/Myc (RM9) and Myc-driven (Myc-CaP) prostate cancer cells expressing the tetracycline-inducible gene Tlr9 (Tlr9ON) or the control LacZ (LacZON). When engrafted into mice and treated with tetracycline, Tlr9ON, but not LacZON, tumors showed accelerated growth kinetics compared with tumors in PBS-treated mice. Tlr9 upregulation in cancer cells triggered the selective accumulation of CD11b+Ly6GHILy6CLO myeloid cells, phenotypically similar to PMN-MDSCs. The PMN-MDSCs from tetracycline-treated RM9-Tlr9ON tumors increased the immunosuppressive activity of the STAT3 transcription factor, thereby more potently inhibiting T cell proliferation. We identified LIF, an IL-6-type cytokine and STAT3 activator, as a potential mediator of crosstalk between TLR9-expressing prostate cancer cells and PMN-MDSCs. Antibody-mediated LIF neutralization reduced the percentage of tumor-infiltrating PMN-MDSCs and inhibited tumor growth in mice. The clinical relevance of LIF is confirmed by the correlation between TLR9 and LIF expression in prostate cancer specimens. Furthermore, blood samples from patients with prostate cancer showed elevated levels of LIF and high LIFR expression on circulating PMN-MDSCs. Our results suggest that TLR9+ prostate cancers promote immune evasion via LIF-mediated expansion and activation of PMN-MDSCs. Finally, targeting TLR9/LIF/STAT3 signaling using oligonucleotide-based inhibitors, such as CpG-STAT3dODN, can offer new opportunities for prostate cancer immunotherapy." @default.
• W2617763968 created "2017-06-05" @default.
• W2617763968 creator A5001135981 @default.
• W2617763968 creator A5007699540 @default.
• W2617763968 creator A5008141411 @default.
• W2617763968 creator A5008219651 @default.
• W2617763968 creator A5022693796 @default.
• W2617763968 creator A5025095801 @default.
• W2617763968 creator A5041033274 @default.
• W2617763968 creator A5041131679 @default.
• W2617763968 creator A5058392939 @default.
• W2617763968 creator A5065771969 @default.
• W2617763968 creator A5075582905 @default.
• W2617763968 creator A5077632020 @default.
• W2617763968 creator A5088549518 @default.
• W2617763968 date "2017-05-22" @default.
• W2617763968 modified "2023-10-16" @default.
• W2617763968 title "TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs" @default.
• W2617763968 cites W1566147296 @default.
• W2617763968 cites W1581834767 @default.
• W2617763968 cites W1824670638 @default.
• W2617763968 cites W1911919368 @default.
• W2617763968 cites W1961309807 @default.
• W2617763968 cites W1972018679 @default.
• W2617763968 cites W1977179270 @default.
• W2617763968 cites W1980255564 @default.
• W2617763968 cites W1996436013 @default.
• W2617763968 cites W2004150448 @default.
• W2617763968 cites W2006234112 @default.
• W2617763968 cites W2006514214 @default.
• W2617763968 cites W2012416768 @default.
• W2617763968 cites W2014139160 @default.
• W2617763968 cites W2044227662 @default.
• W2617763968 cites W2046764077 @default.
• W2617763968 cites W2053404124 @default.
• W2617763968 cites W2059724367 @default.
• W2617763968 cites W2061466636 @default.
• W2617763968 cites W2063452120 @default.
• W2617763968 cites W2074898491 @default.
• W2617763968 cites W2086840459 @default.
• W2617763968 cites W2118278569 @default.
• W2617763968 cites W2134219545 @default.
• W2617763968 cites W2136176800 @default.
• W2617763968 cites W2149570955 @default.
• W2617763968 cites W2160390319 @default.
• W2617763968 cites W2168478794 @default.
• W2617763968 cites W2172085802 @default.
• W2617763968 cites W2185075416 @default.
• W2617763968 cites W2201282822 @default.
• W2617763968 cites W2206971126 @default.
• W2617763968 cites W2235523093 @default.
• W2617763968 cites W2266683146 @default.
• W2617763968 cites W2313700783 @default.
• W2617763968 cites W2508955628 @default.
• W2617763968 cites W2522829580 @default.
• W2617763968 cites W257500189 @default.
• W2617763968 cites W2604910109 @default.
• W2617763968 cites W4236153851 @default.
• W2617763968 doi "https://doi.org/10.1189/jlb.3ma1016-451rr" @default.
• W2617763968 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5505743" @default.
• W2617763968 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28533357" @default.
• W2617763968 hasPublicationYear "2017" @default.
• W2617763968 type Work @default.
• W2617763968 sameAs 2617763968 @default.
• W2617763968 citedByCount "43" @default.
• W2617763968 countsByYear W26177639682018 @default.
• W2617763968 countsByYear W26177639682019 @default.
• W2617763968 countsByYear W26177639682020 @default.
• W2617763968 countsByYear W26177639682021 @default.
• W2617763968 countsByYear W26177639682022 @default.
• W2617763968 countsByYear W26177639682023 @default.
• W2617763968 crossrefType "journal-article" @default.
• W2617763968 hasAuthorship W2617763968A5001135981 @default.
• W2617763968 hasAuthorship W2617763968A5007699540 @default.
• W2617763968 hasAuthorship W2617763968A5008141411 @default.
• W2617763968 hasAuthorship W2617763968A5008219651 @default.
• W2617763968 hasAuthorship W2617763968A5022693796 @default.
• W2617763968 hasAuthorship W2617763968A5025095801 @default.
• W2617763968 hasAuthorship W2617763968A5041033274 @default.
• W2617763968 hasAuthorship W2617763968A5041131679 @default.
• W2617763968 hasAuthorship W2617763968A5058392939 @default.
• W2617763968 hasAuthorship W2617763968A5065771969 @default.
• W2617763968 hasAuthorship W2617763968A5075582905 @default.
• W2617763968 hasAuthorship W2617763968A5077632020 @default.
• W2617763968 hasAuthorship W2617763968A5088549518 @default.
• W2617763968 hasBestOaLocation W26177639681 @default.
• W2617763968 hasConcept C104317684 @default.
• W2617763968 hasConcept C121608353 @default.
• W2617763968 hasConcept C150194340 @default.
• W2617763968 hasConcept C190727270 @default.
• W2617763968 hasConcept C203014093 @default.
• W2617763968 hasConcept C2776107976 @default.
• W2617763968 hasConcept C2778690821 @default.
• W2617763968 hasConcept C2778923194 @default.
• W2617763968 hasConcept C2779138994 @default.
• W2617763968 hasConcept C2780192828 @default.
• W2617763968 hasConcept C2780940892 @default.
• W2617763968 hasConcept C502942594 @default.

• next